Headquartered in La Jolla, CA Fiscal year ends December NASDAQ: CALC calcimedica.com
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The company's pipeline includes two distinct CRAC channel inhibitor compounds: Auxora (zegocractin), an intravenous formulation that has been evaluated in more than 350 patients and is being developed for pulmonary arterial hypertension and acute pancreatitis, and CM5480, an oral CRAC channel inhibitor designed for chronic dosing in pulmonary hypertension. CalciMedica is pre-revenue with no approved products and is focused on advancing clinical trials, including a planned Phase 1b proof-of-concept trial of Auxora in PAH and a planned Phase 2b trial in acute pancreatitis, with key data readouts and an IND submission for CM5480 anticipated in mid-2027. Updated
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases.
The Wall Street consensus 12-month price target for CALC is $50.00.
